High-yield dividend stocks are increasingly favored as a strategy to combat market volatility. Analysts emphasize companies like Pfizer, which, despite challenges post-pandemic, boast a promising oncology drug pipeline and a solid dividend of around 7.3%. Pfizer has consistently increased dividends for 16 years, and predictions suggest yields could rise significantly. With the potential for ongoing revenue generation from the drug pipeline, analysts maintain a positive outlook, making dividend stocks an attractive option for investors looking to increase income and reduce risk in their portfolios.
Wall Street analysts are bullish on dividend stocks, highlighting their ability to provide steady income and mitigate market volatility, especially during downturns.
Pfizer has a strong oncology pipeline with 108 potential drugs, which could continue to drive future revenue and growth, beyond its COVID-19 vaccine successes.
Collection
[
|
...
]